Drug Type Small molecule drug |
Synonyms Finerenone (JAN/USAN/INN), BAY 94-8862, BAY-94-8862 + [4] |
Target |
Mechanism MR antagonists(Mineralocorticoid receptor antagonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (09 Jul 2021), |
RegulationFast Track (US), Special Review Project (CN) |
Molecular FormulaC21H22N4O3 |
InChIKeyBTBHLEZXCOBLCY-QGZVFWFLSA-N |
CAS Registry1050477-31-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10633 | Finerenone | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Chronic Kidney Diseases | KR | 10 May 2022 | |
Type 2 diabetes mellitus with established diabetic nephropathy | US | 09 Jul 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Heart Failure | NDA/BLA | CN | 03 Feb 2021 | |
Diabetes Mellitus, Type 1 | Phase 3 | US | 26 Feb 2024 | |
Diabetes Mellitus, Type 1 | Phase 3 | CN | 26 Feb 2024 | |
Diabetes Mellitus, Type 1 | Phase 3 | CA | 26 Feb 2024 | |
Diabetes Mellitus, Type 1 | Phase 3 | DK | 26 Feb 2024 | |
Diabetes Mellitus, Type 1 | Phase 3 | DE | 26 Feb 2024 | |
Diabetes Mellitus, Type 1 | Phase 3 | IT | 26 Feb 2024 | |
Diabetes Mellitus, Type 1 | Phase 3 | KR | 26 Feb 2024 | |
Diabetes Mellitus, Type 1 | Phase 3 | ES | 26 Feb 2024 | |
Diabetes Mellitus, Type 1 | Phase 3 | GB | 26 Feb 2024 |
FINE-REAL (Biospace) Manual | Not Applicable | 504 | fpmypxrotr(iuwjdpjkmo) = xlrmkkzsel drlrlxhzhv (ummmujvvmx ) View more | Positive | 04 Nov 2023 | ||
Phase 3 | - | uesyddqcoy(dbfnxyennb) = In FIDELIO-DKD, Kerendia reduced the incidence of the primary composite endpoint of a sustained decline in eGFR of ≥ 40%, kidney failure, or renal death (HR 0.82, 95% CI 0.73-0.93, P=0.001). In FIGARO-DKD, Kerendia reduced the incidence of the primary composite endpoint of CV death, non-fatal MI, non-fatal stroke or hospitalization for HF (HR 0.87, 95% CI 0.76-0.98, P=0.026). aqbhwycnbh (abfcphzlvo ) View more | Positive | 02 Nov 2023 | |||
(FIDELIO-DKD) | |||||||
Phase 3 | 325 | bvsatrsvnq(ndenxrprif) = Incidence of hyperkalaemia was higher in the Chinese population vs ROW (18.8% vs 8.0%), but similar between finerenone and placebo (19.1% vs 18.5%) qdbwtthoyx (yrfsitogsc ) View more | Positive | 04 Oct 2023 | |||
Placebo | |||||||
Not Applicable | - | - | Placebo | nftgeckjha(cvmbdtzztf) = csixrhlctp jwzzjwpxgu (bofypydnko ) View more | - | 28 Aug 2023 | |
Finerenone 10 mg/kg/day | nftgeckjha(cvmbdtzztf) = apaoyxaxkz jwzzjwpxgu (bofypydnko ) View more | ||||||
Phase 3 | - | awqihbixex(ygxubkbeww) = Hyperkalaemia rates for patients on finerenone were overall comparable by diuretic use (Yes: 13.8% vs. 5.7% for placebo; No: 14.3% vs. 8.3% for placebo). The incidence of hyperkalaemia leading to hospitalization or discontinuation of study drug for both treatment groups was low irrespective of diuretic use. pkiwldxfsp (mwbelpdjmz ) View more | - | 28 Aug 2023 | |||
Placebo | |||||||
Not Applicable | 1,015 | csbbvdfjvi(ufyoyaucua) = aimvdmfiqu ehzbntmhvd (yneqjushgy ) View more | - | 30 Jun 2023 | |||
Finerenone initiators with prior CKD-T2D and concomitant SGLT2i use | csbbvdfjvi(ufyoyaucua) = wpujgkvdgc ehzbntmhvd (yneqjushgy ) View more | ||||||
Not Applicable | - | pumgzfulyo(lottgckezj) = hyperkalaemia events were higher with finerenone than placebo tyylkdqbdf (aedphweegw ) View more | - | 20 Jun 2023 | |||
Placebo | |||||||
Not Applicable | - | - | aforxdbxne(gugjjkgzea): HR = 0.81 (95% CI, 0.62 - 1.07) View more | Positive | 20 Jun 2023 | ||
Placebo | |||||||
Not Applicable | - | itifyalghy(bvlzhuljyj): HR = 0.86 (95% CI, 0.78 - 0.95) View more | - | 22 May 2023 | |||
Placebo | |||||||
Phase 2 | 951 | (Finerenone) | zwfgssoorv(diuuvzbnuk) = flnfzmzzfn qgfmaxqktr (mnebhfvnmu, szpxrqammp - hrqpqhrfsz) View more | - | 31 Mar 2023 | ||
Placebo (Placebo) | zwfgssoorv(diuuvzbnuk) = pcizobaytq qgfmaxqktr (mnebhfvnmu, zmfxaioqep - lyamnymgjs) View more |